Renal transplant outcomes in patients with autosomal dominant tubulointerstitial kidney disease.
ADTKD
genetics
graft survival
kidney disease
rare renal disease
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
15
09
2019
revised:
30
12
2019
accepted:
07
01
2020
pubmed:
21
1
2020
medline:
24
6
2021
entrez:
21
1
2020
Statut:
ppublish
Résumé
Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a rare genetic cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD). We aimed to compare renal transplant outcomes in people with ESRD due to ADTKD to those with other causes of renal failure. Patients with clinical characteristics consistent with ADTKD by the criteria outlined in the 2015 KDIGO consensus were included. We compared ADTKD transplant outcomes with those of 4633 non-ADTKD renal transplant recipients. We included 31 patients who met diagnostic criteria for ADTKD in this analysis, 23 of whom had an identified mutation (28 were categorized as definite-ADTKD and 3 as suspected ADTKD). Five patients received a second transplant during follow-up. In total, 36 grafts were included. We did not identify significant differences between groups in terms of graft or patient survival after transplantation. Twenty-five transplant biopsies were performed during follow-up, and none of these showed signs of recurrent ADTKD post-transplant. In patients with ESRD due to ADTKD, we demonstrate that transplant outcomes are comparable with the general transplant population. There is no evidence that ADTKD can recur after transplantation.
Substances chimiques
Uromodulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13783Subventions
Organisme : Wellcome Trust
ID : 203930/B/16/Z
Pays : United Kingdom
Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Bleyer AJ, Kmoch S. Autosomal dominant tubulointerstitial kidney disease: of names and genes. Kidney Int. 2014;86:459-461.
Gast C, Marinaki A, Arenas-Hernandez M, et al. Autosomal dominant tubulointerstitial kidney disease-UMOD is the most frequent non polycystic genetic kidney disease. BMC Nephrol. 2018;19:301.
Devuyst O, Olinger E, Weber S, et al. Autosomal dominant tubulointerstitial kidney disease. Nat Rev Dis Primers. 2019;5:60.
Dahan K, Devuyst O, Smaers M, et al. A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol. 2003;14:2883-2893.
Eckardt KU, Alper SL, Antignac C, et al. Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management - A KDIGO consensus report. Kidney Int. 2015;88:676-683.
Faguer S, Decramer S, Chassaing N, et al. Diagnosis, management, and prognosis of HNF1B nephropathy in adulthood. Kidney Int. 2011;80:768-776.
Kirby A, Gnirke A, Jaffe DB, et al. Mutations causing medullary cystic kidney disease type 1 lie in a large VNTR in MUC1 missed by massively parallel sequencing. Nat Genet. 2013;45:299-303.
Bolar Nikhita A, Golzio C, Živná M, et al. Heterozygous loss-of-function <em>SEC61A1</em> mutations cause autosomal-dominant tubulo-interstitial and glomerulocystic kidney disease with anemia. Am J Hum Genet. 2016;99:174-187.
Zaucke F, Boehnlein JM, Steffens S, et al. Uromodulin is expressed in renal primary cilia and UMOD mutations result in decreased ciliary uromodulin expression. Hum Mol Genet. 2010;19:1985-1997.
Bleyer AJ, Kidd K, Živná M, Kmoch S. Autosomal dominant tubulointerstitial kidney disease. Adv Chronic Kidney Dis. 2017;24:86-93.
Bleyer AJ Jr, Hart PS, Kmoch S. Autosomal Dominant Tubulointerstitial Kidney Disease. UMOD-Related. Gene Reviews. Seattle: University of Washington; 2007.
Kostro JZ, Hellmann A, Kobiela J, et al. Quality of life after kidney transplantation: a prospective study. Transpl Proc. 2016;48:50-54.
Oniscu GC, Brown H, Forsythe JLR. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol. 2005;16:1859-1865.
Stavrou C, Deltas CC, Christophides TC, Pierides A. Outcome of kidney transplantation in autosomal dominant medullary cystic kidney disease type 1. Nephrol Dial Transplant. 2003;18:2165-2169.
Soloukides AP, Moutzouris DAD, Papagregoriou GN, Stavrou CV, Deltas CC, Tzanatos HA. Renal graft outcome in autosomal dominant medullary cystic kidney disease type 1. J Nephrol. 2013;26:793-798.
Connaughton DM, Bukhari S, Conlon P, et al. The irish kidney gene project-prevalence of family history in patients with kidney disease in Ireland. Nephron. 2015;130:293-301.
Mann N, Braun DA, Amann K, et al. Whole-exome sequencing enables a precision medicine approach for kidney transplant recipients. J Am Soc Nephrol. 2019;30:201-215.
Blumenstiel B, DeFelice M, Birsoy O, et al. Development and validation of a mass spectrometry-based assay for the molecular diagnosis of mucin-1 kidney disease. J Mol Diagn. 2016;18:566-571.
Živná M, Kidd K, Přistoupilová A, et al. Noninvasive immunohistochemical diagnosis and novel %3cem%3eMUC1%3c/em%3e mutations causing autosomal dominant tubulointerstitial kidney disease. J Am Soc Nephrol. 2018;29:2418.
Cormican S, Connaughton DM, Kennedy C, et al. Autosomal dominant tubulointerstitial kidney disease (ADTKD) in Ireland. Ren Fail. 2019;41:832-841.
Green A, Allos M, Donohoe J, Carmody M, Walshe J. Prevalence of hereditary renal disease. Ir Med J. 1990;83:11-13.
Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol. 2013;17:317-326.
Devuyst O, Knoers NVAM, Remuzzi G, Schaefer F. Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet. 2014;383:1844-1859.
Connaughton DM, Kennedy C, Shril S, et al. Monogenic causes of chronic kidney disease in adults. Kidney Int. 95:914-928.
McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297-1303.
Johnston O, O'Kelly P, Donohue J, et al. Favorable graft survival in renal transplant recipients with polycystic kidney disease. Ren Fail. 2005;27:309-314.